August 20, 2006 – Biotech enjoyed a blissful late summer week, with the Centient Biotech 200™ rising 122 points to 3706.23, a gain of 3.4%. Breadth was nothing short of tremendous: 188 biotechs moved higher and just 26 companies declined. In the IPO sector, ActivBiotics and Emergent Biosolutions filed their initial submissions. Poinard rose 42% on news its oncology drug made clinical progress; Acadia was the beneficiary of a Buy recommendation from Bank of America; Bioenvision moved higher after receiving an Overweight rating from Prudential; Impax Labs rose on news the company’s founder once again took on the CEO position; and Keryx received continued support from Jeffries, bouncing off a new low. More details...
